These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

396 related items for PubMed ID: 27605087

  • 1. New developments in anti-sickling agents: can drugs directly prevent the polymerization of sickle haemoglobin in vivo?
    Oder E, Safo MK, Abdulmalik O, Kato GJ.
    Br J Haematol; 2016 Oct; 175(1):24-30. PubMed ID: 27605087
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. A Triazole Disulfide Compound Increases the Affinity of Hemoglobin for Oxygen and Reduces the Sickling of Human Sickle Cells.
    Nakagawa A, Ferrari M, Schleifer G, Cooper MK, Liu C, Yu B, Berra L, Klings ES, Safo RS, Chen Q, Musayev FN, Safo MK, Abdulmalik O, Bloch DB, Zapol WM.
    Mol Pharm; 2018 May 07; 15(5):1954-1963. PubMed ID: 29634905
    [Abstract] [Full Text] [Related]

  • 5. Quantitative prediction of erythrocyte sickling for the development of advanced sickle cell therapies.
    Lu L, Li Z, Li H, Li X, Vekilov PG, Karniadakis GE.
    Sci Adv; 2019 Aug 07; 5(8):eaax3905. PubMed ID: 31457104
    [Abstract] [Full Text] [Related]

  • 6. Targeting HbS Polymerization.
    Ferrone FA.
    Semin Hematol; 2018 Apr 07; 55(2):53-59. PubMed ID: 30616807
    [Abstract] [Full Text] [Related]

  • 7. Interactions of an Anti-Sickling Drug with Hemoglobin in Red Blood Cells from a Patient with Sickle Cell Anemia.
    Strader MB, Liang H, Meng F, Harper J, Ostrowski DA, Henry ER, Shet AS, Eaton WA, Thein SL, Alayash AI.
    Bioconjug Chem; 2019 Mar 20; 30(3):568-571. PubMed ID: 30794381
    [Abstract] [Full Text] [Related]

  • 8. Antisickling effect of chrysin is associated with modulation of oxygenated and deoxygenated haemoglobin via alteration of functional chemistry and metabolic pathways of human sickle erythrocytes.
    Nwankwo HC, Idowu AA, Muhammad A, Waziri AD, Abubakar YS, Bashir M, Erukainure OL.
    Hum Exp Toxicol; 2021 Dec 20; 40(12_suppl):S108-S124. PubMed ID: 34151613
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Treatment of sickle cell disease by increasing oxygen affinity of hemoglobin.
    Henry ER, Metaferia B, Li Q, Harper J, Best RB, Glass KE, Cellmer T, Dunkelberger EB, Conrey A, Thein SL, Bunn HF, Eaton WA.
    Blood; 2021 Sep 30; 138(13):1172-1181. PubMed ID: 34197597
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Design, Synthesis, and Evaluation of Allosteric Effectors for Hemoglobin.
    Enakaya NA, Jefferson A, Chew-Martinez D, Matthews JS.
    Acc Chem Res; 2023 Jun 06; 56(11):1279-1286. PubMed ID: 36946781
    [Abstract] [Full Text] [Related]

  • 14. Targeted modification of furan-2-carboxaldehydes into Michael acceptor analogs yielded long-acting hemoglobin modulators with dual antisickling activities.
    Omar AM, Abdulmalik O, El-Say KM, Ghatge MS, Cyril-Olutayo M, Paredes S, Al-Awadh M, El-Araby ME, Safo MK.
    Chem Biol Drug Des; 2024 Jan 06; 103(1):e14371. PubMed ID: 37798397
    [Abstract] [Full Text] [Related]

  • 15. An Investigation of Structure-Activity Relationships of Azolylacryloyl Derivatives Yielded Potent and Long-Acting Hemoglobin Modulators for Reversing Erythrocyte Sickling.
    Omar AM, Abdulmalik O, Ghatge MS, Muhammad YA, Paredes SD, El-Araby ME, Safo MK.
    Biomolecules; 2020 Nov 02; 10(11):. PubMed ID: 33147875
    [Abstract] [Full Text] [Related]

  • 16. The delay time in sickle cell disease after 40 years: A paradigm assessed.
    Ferrone FA.
    Am J Hematol; 2015 May 02; 90(5):438-45. PubMed ID: 25645011
    [Abstract] [Full Text] [Related]

  • 17. Identification of a small molecule that increases hemoglobin oxygen affinity and reduces SS erythrocyte sickling.
    Nakagawa A, Lui FE, Wassaf D, Yefidoff-Freedman R, Casalena D, Palmer MA, Meadows J, Mozzarelli A, Ronda L, Abdulmalik O, Bloch KD, Safo MK, Zapol WM.
    ACS Chem Biol; 2014 Oct 17; 9(10):2318-25. PubMed ID: 25061917
    [Abstract] [Full Text] [Related]

  • 18. MetAP2 inhibition modifies hemoglobin S to delay polymerization and improves blood flow in sickle cell disease.
    Demers M, Sturtevant S, Guertin KR, Gupta D, Desai K, Vieira BF, Li W, Hicks A, Ismail A, Gonçalves BP, Di Caprio G, Schonbrun E, Hansen S, Musayev FN, Safo MK, Wood DK, Higgins JM, Light DR.
    Blood Adv; 2021 Mar 09; 5(5):1388-1402. PubMed ID: 33661300
    [Abstract] [Full Text] [Related]

  • 19. Structural basis for the potent antisickling effect of a novel class of five-membered heterocyclic aldehydic compounds.
    Safo MK, Abdulmalik O, Danso-Danquah R, Burnett JC, Nokuri S, Joshi GS, Musayev FN, Asakura T, Abraham DJ.
    J Med Chem; 2004 Sep 09; 47(19):4665-76. PubMed ID: 15341482
    [Abstract] [Full Text] [Related]

  • 20. 5-hydroxymethyl-2-furfural modifies intracellular sickle haemoglobin and inhibits sickling of red blood cells.
    Abdulmalik O, Safo MK, Chen Q, Yang J, Brugnara C, Ohene-Frempong K, Abraham DJ, Asakura T.
    Br J Haematol; 2005 Feb 09; 128(4):552-61. PubMed ID: 15686467
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.